Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Clatterbridge Cancer Centre NHS FT

6 abstracts

Abstract
Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).
Org: Institute of Clinical Medicine, University of Oslo, Institute of Clinical Sciences, Department of Surgery, The Sahlgrenska Academy, University of Gothenburg, Department of Biomedical and Clinical Sciences, Linköping University, Clatterbridge Cancer Centre NHS FT, School of Health Sciences, University of Skövde,
Abstract
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.
Org: Royal Marsden Hospital NHS Foundation Trust, Medical Oncology Service, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), National and Kapodistrian University of Athens,
Abstract
Radiation dose esclation with contact X-ray brachytherapy (Papillon) and quality of life in patients with rectal cancer: Results from the phase 3 randomised trial OPERA.
Org: University of Liverpool, Centre Antoine Lacassagne, Clatterbridge Cancer Centre NHS FT, Imperial College,
Abstract
ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem).
Org: University of Manchester/The Christie NHS Foundation Trust, Manchester, United Kingdom, Cardiff University School of Medicine, Cardiff, United Kingdom, The Christie and Salford Royal Hospital NHS Foundation Trusts,
Abstract
Incidence of immune checkpoint inhibitor induced myocarditis in patients with mesothelioma from a regional tertiary cancer centre covering a patient population of 2.6 million.
Org: Clatterbridge Cancer Centre NHS FT, Liverpool Hospital Anatomical Pathology, Wirral,
Abstract
Association of tertiary lymphoid structures with outcomes from PD-1 inhibition in advanced malignant pleural mesothelioma.
Org: Centre Hospitalier Universitaire Vaudois, Frontier Science Foundation - Hellas, Immune Landscape Laboratory, Centre Thérapies expérimentales, Department of Oncology, CHUV - Centre Hospitalier Universitaire Vaudois,